National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study

Cancer

Volumn 122, Issue 10, 2016, Pages 1505-1512

  Mahal, Brandon A ^a   Chen, Yu Wei ^a   Efstathiou, Jason A ^a,b   Muralidhar, Vinayak ^a   Hoffman, Karen E ^c   Yu, James B ^d   Feng, Felix Y ^e   Beard, Clair J ^a   Martin, Neil E ^a   Orio, Peter F ^a   Nguyen, Paul L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

patterns of care; prostatic neoplasm; proton therapy; radiotherapy

Indexed keywords

AGE; AGED; ARTICLE; BLACK PERSON; CANCER REGISTRY; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HISPANIC; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; TREND STUDY; URBAN AREA; PROSTATIC NEOPLASMS; REGISTER; STATISTICAL MODEL; UNITED STATES; UTILIZATION;

AGED; HUMANS; LOGISTIC MODELS; MALE; PROSTATIC NEOPLASMS; PROTON THERAPY; REGISTRIES; UNITED STATES;

EID: 84960436934     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29960     Document Type: Article

References (23)

1. Siegel RL, Miller KD, Jemal A,. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29.
2. Nguyen PL, Gu X, Lipsitz SR, et al., Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011; 29: 1517-1524.
3. Wisenbaugh ES, Andrews PE, Ferrigni RG, et al., Proton beam therapy for localized prostate cancer 101: basics, controversies, and facts. Rev Urol. 2014; 16: 67-75.
4. Hoppe BS, Bryant C, Sandler HM,. Radiation for prostate cancer: intensity modulated radiation therapy versus proton beam. J Urol. 2015; 193: 1089-1091.
5. Efstathiou JA, Gray PJ, Zietman AL,. Proton beam therapy and localised prostate cancer: current status and controversies. Br J Cancer. 2013; 108: 1225-1230.
6. Shah A, Paly JJ, Efstathiou JA, Bekelman JE,. Physician evaluation of internet health information on proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013; 85: e173-e177.
7. The National Association for Proton Therapy. Proton therapy centers. http://www.proton-therapy.org/map.htm. Accessed August 20, 2015.
8. Lerro CC, Robbins AS, Phillips JL, Stewart AK,. Comparison of cases captured in the National Cancer Data Base with those in population-based central cancer registries. Ann Surg Oncol. 2013; 20: 1759-1765.
9. American College of Surgeons. National Cancer Data Base. https://www.facs.org/quality%20programs/cancer/ncdb. Accessed December 30, 2014.
10. US Census Bureau. American Community Survey (ACS) data. https://www.census.gov/programs-surveys/acs/data.html. Accessed December 27, 2014.
11. United States Department of Agriculture Economic Research Service. Rural-urban continuum codes. http://www.ers.usda.gov/data-products/rural-urban-continuum-codes.aspx. Accessed December 27, 2013.
12. Winslow R, Martin TW,. Prostate-cancer therapy comes under attack. The Wall Street Journal. August 28, 2013. http://www.wsj.com/article-email/SB10001424127887324324404579041271367621000-lMyQjAxMTAzMDIwOTEyNDkyWj.html?mod=wsj-valettop-email. Accessed August 20, 2015.
13. Institute for Clinical and Economic Review. Brachytherapy and proton beam therapy for treatment of clinically-localized, low-risk prostate cancer. www.nomos.com/pdf/ICER.pdf. Accessed August 20, 2015.
14. Yu JB, Soulos PR, Herrin J, et al., Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013; 105: 25-32.
15. Sheets NC, Goldin GH, Meyer AM, et al., Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012; 307: 1611-1620.
16. ClinicalTrials.gov. Proton therapy vs. IMRT for low or intermediate risk prostate cancer (PARTIQoL). https://clinicaltrials.gov/ct2/show/NCT01617161. Accessed August 23, 2015.
17. Presley CJ, Raldow AC, Cramer LD, et al., A new approach to understanding racial disparities in prostate cancer treatment. J Geriatr Oncol. 2013; 4: 1-8.
18. Aboagye JK, Kaiser HE, Hayanga AJ,. Rural-urban differences in access to specialist providers of colorectal cancer care in the United States: a physician workforce issue. JAMA Surg. 2014; 149: 537-543.
19. Chornokur G, Dalton K, Borysova ME, Kumar NB,. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate. 2011; 71: 985-997.
20. Ryoo JJ, Ordin DL, Antonio AL, et al., Patient preference and contraindications in measuring quality of care: what do administrative data miss? J Clin Oncol. 2013; 31: 2716-2723.
21. Green AR, Carney DR, Pallin DJ, et al., Implicit bias among physicians and its prediction of thrombolysis decisions for black and white patients. J Gen Intern Med. 2007; 22: 1231-1238.
22. Teal CR, Gill AC, Green AR, Crandall S,. Helping medical learners recognise and manage unconscious bias toward certain patient groups. Med Educ. 2012; 46: 80-88.
23. Schulman KA, Berlin JA, Harless W, et al., The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med. 1999; 340: 618-626.